BOLD-100 with chemo for advanced gut cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (and can follow the study’s birth-control rules if needed).
- You have confirmed advanced gastrointestinal cancer that cannot be removed or has spread, and for one study group you had only one previous treatment line for metastatic disease.
- Your cancer has measurable spots that can be tracked by scans, and you are expected to live at least 16 weeks.
- You can move around and do daily activities fairly well (ECOG 0–1).
- Your organs (like liver, kidneys, and blood counts) are working well enough for treatment.
- In the main study arm, your tumor is BRAF wild-type (and not MSI-H), and you haven’t had prior BOLD-100.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.